Surgical treatment of patients with initially inoperable and/or metastatic gastrointestinal stromal tumors (GIST) during therapy with imatinib mesylate
- 22 February 2006
- journal article
- research article
- Published by Wiley in Journal of Surgical Oncology
- Vol. 93 (4), 304-311
- https://doi.org/10.1002/jso.20466
Abstract
Background The aim of the study was to analyze the surgical possibilities of unresectable and/or metastatic GIST CD117(+) patients during imatinib treatment. Methods We analyzed the results of surgery in 141 patients treated with imatinib for initially inoperable and/or metastatic GIST CD117(+). Median follow-up time was 12 months (range: 3–26). Results Surgery was performed as subsequent treatment in 24 patients (Group I, 17%) for resection of residual disease after complete/partial response and lack of further response to imatinib and as salvage therapy in eight patients (Group II, 6%), who progressed on initially successful imatinib therapy. In Group I, the viable GIST cells were not detected histologically in only three resection specimens. The first five patients in Group I did not receive imatinib further and we observed four recurrences. In next 19 patients, continuing imatinib after surgery, we observed only one relapse. In Group II, we continued imatinib therapy after high-risk surgical procedures, but in five patients we observed subsequent progression. Conclusions Surgical removal of residual disease during imatinib treatment may allow for complete remission in selected GIST patients after response to therapy, theoretically prolonging durable remission, but it is necessary to continue imatinib for its maintenance. J. Surg. Oncol. 2006;93:304–311.Keywords
This publication has 24 references indexed in Scilit:
- Gastric GI stromal tumors (GISTs): The role of surgery in the era of targeted therapyJournal of Surgical Oncology, 2005
- Surgery for gastrointestinal stromal tumour in the post‐imatinib eraAnz Journal of Surgery, 2005
- Gastrointestinal stromal tumors: The incidence, prevalence, clinical course, and prognostication in the preimatinib mesylate eraCancer, 2005
- Prognostic factors after surgery of primary resectable gastrointestinal stromal tumoursEuropean Journal of Surgical Oncology, 2004
- Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trialThe Lancet, 2004
- Gastro-intestinal stromal tumors (GIST) - Current aspects of surgical managementDeutsche Medizinische Wochenschrift (1946), 2004
- Surgery and Imatinib in the Management of GIST: Emerging Approaches to Adjuvant and Neoadjuvant TherapyAnnals of Surgical Oncology, 2004
- Efficacy and Safety of Imatinib Mesylate in Advanced Gastrointestinal Stromal TumorsNew England Journal of Medicine, 2002
- Salvage surgery for patients with recurrent gastrointestinal sarcomaCancer, 2000
- Gain-of-Function Mutations of c- kit in Human Gastrointestinal Stromal TumorsScience, 1998